31 – 40 of 92
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of Ra-223-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
- Contribution to journal › Article
-
Mark
An electrophysiologist perspective on risk stratification in heart failure: can better understanding of the condition of the cardiac sympathetic nervous system help?
- Contribution to journal › Article
-
Mark
The water-perfusable tissue fraction of colorectal cancer metastases is increased by the selective PDGF-receptor inhibitor imatinib but not the IL-1 receptor antagonist anakinra, a study using serial dynamic 15O-water PET.
- Contribution to journal › Article
-
Mark
Intratherapeutic Biokinetic Measurements, Dosimetry Parameters Estimate, and Monitoring Treatment Efficacy using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy.
- Contribution to journal › Article
-
Mark
Long-term retention of 177Lu/177mLu-Dotatate in patients investigated by gamma spectrometry and gamma camera imaging.
- Contribution to journal › Article
-
Mark
Radioimmunoimaging and Radioimmunotherapy of Prostate Cancer. Preclinical evaluation of kallikrein related peptidase 2 targeting
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
A Compartmental Model of Mouse Thrombopoiesis and Erythropoiesis to Predict Bone Marrow Toxicity After Internal Irradiation.
- Contribution to journal › Article
-
Mark
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment
(2014) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 55(11). p.8-1842
- Contribution to journal › Article
-
Mark
In vivo evaluation of 177Lu-labeled h11B6, a humanized antibody for hK2 targeting in prostate cancer
- Contribution to journal › Published meeting abstract
-
Mark
Combining optical Cherenkov luminescence imaging and SPECT for intratherapy dosimetry in preclinical radionuclide therapy
- Contribution to journal › Published meeting abstract
